JP2023521036A5 - - Google Patents
Info
- Publication number
- JP2023521036A5 JP2023521036A5 JP2022560245A JP2022560245A JP2023521036A5 JP 2023521036 A5 JP2023521036 A5 JP 2023521036A5 JP 2022560245 A JP2022560245 A JP 2022560245A JP 2022560245 A JP2022560245 A JP 2022560245A JP 2023521036 A5 JP2023521036 A5 JP 2023521036A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- salt form
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025102055A JP2025120501A (ja) | 2020-04-03 | 2025-06-18 | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 | |
| US63/005,153 | 2020-04-03 | ||
| PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025102055A Division JP2025120501A (ja) | 2020-04-03 | 2025-06-18 | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521036A JP2023521036A (ja) | 2023-05-23 |
| JP2023521036A5 true JP2023521036A5 (https=) | 2024-04-11 |
| JP7748386B2 JP7748386B2 (ja) | 2025-10-02 |
Family
ID=75674969
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560245A Active JP7748386B2 (ja) | 2020-04-03 | 2021-04-02 | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 |
| JP2025102055A Pending JP2025120501A (ja) | 2020-04-03 | 2025-06-18 | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025102055A Pending JP2025120501A (ja) | 2020-04-03 | 2025-06-18 | がんの治療で使用するためのミルダメチニブ及びリフィラフェニブの同時投与 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230128315A1 (https=) |
| EP (1) | EP4125842B1 (https=) |
| JP (2) | JP7748386B2 (https=) |
| KR (1) | KR20230048476A (https=) |
| CN (1) | CN116194095B (https=) |
| AU (1) | AU2021246141A1 (https=) |
| BR (1) | BR112022019914A2 (https=) |
| CA (1) | CA3174223A1 (https=) |
| CL (1) | CL2022002682A1 (https=) |
| CO (1) | CO2022015891A2 (https=) |
| DK (1) | DK4125842T3 (https=) |
| ES (1) | ES2985012T3 (https=) |
| FI (1) | FI4125842T3 (https=) |
| HU (1) | HUE067894T2 (https=) |
| IL (1) | IL296878A (https=) |
| MX (1) | MX2022012351A (https=) |
| PE (1) | PE20231211A1 (https=) |
| PL (1) | PL4125842T3 (https=) |
| PT (1) | PT4125842T (https=) |
| TW (1) | TWI893097B (https=) |
| WO (1) | WO2021202981A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3254428A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | TREATMENT OF PLEXIFORM NEUROFIBROMAS (NP) ASSOCIATED WITH TYPE 1 NEUROFIBROMATOSIS (NF1) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB |
| WO2023178276A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| JP2025534589A (ja) * | 2022-10-14 | 2025-10-17 | スプリングワークス、セラピューティクス、インコーポレイテッド | がんの治療に使用するための併用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013148817A (ru) * | 2011-04-01 | 2015-05-10 | Дженентек, Инк. | Комбинации соединений-ингибиторов акт и мек и способы их применения |
| CN113307805A (zh) * | 2015-04-15 | 2021-08-27 | 百济神州有限公司 | B-raf激酶抑制剂的马来酸盐、其结晶形式、制备方法和用途 |
| WO2019113345A1 (en) * | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
-
2021
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 US US17/995,002 patent/US20230128315A1/en active Pending
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023521036A5 (https=) | ||
| KR20120101456A (ko) | 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 | |
| JP2014515373A5 (https=) | ||
| KR102490547B1 (ko) | 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물 | |
| FI4125842T3 (fi) | Mirdametinibin ja lifirafenibin yhteisantaminen käytettäväksi hoidettaessa syöpiä | |
| JP2012522837A5 (https=) | ||
| KR100894465B1 (ko) | 레보도파의 지속적 효과를 위한 조성물 및 제형 | |
| CN107296811A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| WO2016091165A1 (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| AU2017315357A1 (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| JP2023011549A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| CN112533600B (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| WO2019174590A1 (zh) | 用于治疗三阴性乳腺癌的喹啉衍生物 | |
| CN115243686B (zh) | 丁基苯酞及其衍生物的用途 | |
| TW202327579A (zh) | Ｔｅａｄ抑制劑的給藥方案 | |
| TW201806599A (zh) | 用於快速開始抗抑鬱作用之給藥方案 | |
| CN115487188A (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| WO2019241495A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure | |
| CN106038566A (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
| CN120603593A (zh) | 治疗乳腺癌的方法 | |
| EP2046321A2 (en) | Pharmaceutical composition containing bicalutamide and a method for its use | |
| WO2022047196A1 (en) | Pten inhibitors for treatment and prevention of bone marrow loss | |
| CA2473602A1 (en) | Oral pediatric trimethobenzamide formulations and methods | |
| CN121130092A (zh) | 抗hiv药物在抑制非小细胞肺癌耐药中的应用 |